[
  {
    "question": "A patient came with history of unilateral headache, severe, less than 5 minutes, stabbing pain, unilateral, associated with autonomic symptoms on same side (tearing) best approach:",
    "option_a": "Indomethacin",
    "option_b": "Topamax",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This case describes a headache that is unilateral, very severe, short lasting (<5 minutes) and associated with ipsilateral autonomic features (tearing). This presentation is most consistent with a trigeminal autonomic cephalalgia \u2013 specifically, paroxysmal hemicrania. The defining feature of paroxysmal hemicrania is its absolute responsiveness to indomethacin. Paroxysmal hemicrania, like other trigeminal autonomic cephalalgias, is believed to involve hypothalamic activation that drives the trigeminal-autonomic reflex, resulting in unilateral pain with autonomic symptoms. Abnormal prostaglandin metabolism\u2014and its modulation by indomethacin\u2014plays a key role in its pathogenesis, as evidenced by the dramatic therapeutic response to indomethacin. Patients experience frequent, brief attacks (typically 2 to 30 minutes) of severe unilateral pain. Accompanying autonomic features such as lacrimation and nasal congestion help distinguish it from other headache disorders. In contrast, trigeminal neuralgia (seconds-long pain without prominent autonomic signs) or cluster headache (longer duration, 15\u2013180 minutes) are differentiated based on duration and associated features. The diagnosis is made by careful history and a therapeutic challenge with indomethacin. Differential diagnoses include cluster headache (typically longer duration and with a different pattern of restlessness), SUNCT/SUNA syndromes, and trigeminal neuralgia. The clear-cut response to indomethacin clinches the diagnosis of paroxysmal hemicrania. The first-line treatment is indomethacin. A diagnostic/therapeutic indomethacin trial is standard, with most patients showing complete remission with adequate dosing. Alternative therapies are generally reserved for patients who cannot tolerate indomethacin. In pregnant or lactating patients, indomethacin is generally avoided especially in the third trimester (due to the risk of premature closure of the fetal ductus arteriosus) and alternative management strategies or adjusted dosing with close monitoring may be warranted. Option A (Indomethacin) is the correct treatment given the condition\u2019s indomethacin responsiveness. Option B (Topamax) is more often used in migraine or as a secondary prophylactic agent in some headache disorders, but it is not the first-line treatment in paroxysmal hemicrania. Options C and D are not provided. 1. Paroxysmal hemicrania attacks, though brief, occur many times a day and are exquisitely responsive to indomethacin. 2. Always differentiate it from cluster headache and trigeminal neuralgia by noting both the attack duration and the pattern of autonomic symptoms. Recent guidelines and literature continue to underscore indomethacin as the gold standard for paroxysmal hemicrania, reinforcing its unique therapeutic response. Investigations into the hypothalamic mechanisms continue to refine understanding and aid in distinguishing TAC subtypes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Young man with history of 15-20 minutes, over his orbit, associated with nasal congestion, and his wife noticed that he\u2019s becoming irritated and angry, what is the treatment:",
    "option_a": "Indomethacin",
    "option_b": "High flow Oxygen",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "This scenario describes a young man experiencing unilateral orbital pain lasting 15-20 minutes, associated with nasal congestion and behavioral changes (irritability and anger). These features fit the classic presentation of a cluster headache, which is known for its short, intense attacks accompanied by autonomic symptoms. Cluster headaches are believed to be related to activation of the posterior hypothalamus leading to stimulation of the trigeminal-autonomic reflex. This results in the severe unilateral pain and accompanying features such as lacrimation, nasal congestion, and restlessness/irritability during attacks. Clinically, patients present with stereotypical, recurring attacks that are extremely painful, typically around the orbital region. The associated nasal congestion and the patient\u2019s behavioral changes (agitation) are highly indicative of cluster headache. Differential diagnoses include paroxysmal hemicrania (which has shorter attacks and absolute indomethacin response), migraine (typically longer and with associated nausea/photophobia), and SUNCT \u2013 though the latter usually features very brief attacks. Cluster headache is distinguished by its duration (15\u2013180 minutes), severity, and prominent autonomic symptoms. For acute attacks, high-flow oxygen at 12\u201315 L/min via a non-rebreather mask is the first-line treatment, providing rapid relief. Alternatives include subcutaneous sumatriptan. In pregnant or lactating women, oxygen is considered safe, making it an ideal first-line option during these periods. Option B (High Flow Oxygen) is the correct acute treatment for cluster headache. Option A (Indomethacin) would be more appropriate for paroxysmal hemicrania. Other options, not provided in the question, do not align with established first-line treatments for cluster headache. 1. High-flow oxygen (12\u201315 L/min) is extremely effective in aborting a cluster headache attack. 2. Recognize cluster headache by its very intense periorbital pain combined with prominent autonomic features and restlessness during an attack. Recent clinical guidelines continue to support high-flow oxygen as the first-line acute treatment for cluster headaches. There is ongoing research into the underlying mechanisms of hypothalamic dysfunction in cluster headaches, further validating the current management protocols.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "35 y/o male who came with history of 1 to 1.5 hour of headache with nasal congestion and tearing and left facial swelling that occurs every year lasts for 1 to 1.5 months then he no longer gets any headache during the year, what to the best treatment:",
    "option_a": "Calcium channel blocker",
    "option_b": "Valproic acid",
    "option_c": "Lamotrigine",
    "option_d": "Amitriptyline",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This question describes a 35-year-old male experiencing headaches that last about 1 to 1.5 hours, with associated nasal congestion, tearing, and even facial swelling. These periodic, seasonal episodes, lasting 1 to 1.5 months each year, are classical for episodic cluster headache, where prophylactic treatment is indicated. Episodic cluster headache is mediated by hypothalamic dysfunction which activates the trigeminal-autonomic reflex resulting in unilateral pain and autonomic symptoms. The periodic nature of the headaches is partly explained by circadian and circannual rhythms influenced by the hypothalamus. Patients typically experience cluster headache attacks in bouts lasting weeks to months, followed by prolonged remission periods. The combination of unilateral pain, nasal congestion, tearing, and even facial swelling correlates with alterations in the autonomic nervous system during these bouts. Differential diagnoses include paroxysmal hemicrania (shorter duration and indomethacin responsiveness) and migraine (often longer duration with photophobia and nausea). Cluster headaches are distinguished by their cyclical pattern, unilateral autonomic features, and the relatively short duration of each attack. Verapamil, a calcium channel blocker, is the first-line prophylactic treatment for cluster headache. If verapamil is contraindicated or not tolerated, alternatives such as corticosteroids or lithium may be considered. In pregnant or lactating women, the use of verapamil requires careful consideration with risks and benefits weighed, as data are limited; non-pharmacologic measures or alternative prophylactic strategies might be preferred in such cases. Option A (Calcium channel blocker) is correct because verapamil is the established first-line prophylaxis for cluster headache. Option B (Valproic acid), Option C (Lamotrigine), and Option D (Amitriptyline) are primarily used in other headache disorders such as migraine prevention, but not as first-line agents in cluster headache prophylaxis. 1. Verapamil is the gold standard prophylactic treatment for cluster headache. 2. Cluster headaches typically occur in cyclical patterns with defined cluster periods and remission intervals. Current guidelines and evidence consistently endorse verapamil as the first-line agent for cluster headache prophylaxis, with ongoing studies focusing on optimizing dosing and monitoring for cardiac effects.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "which of the following neurotransmitters has a role in pathogenesis of migraine headache:",
    "option_a": "Serotonin",
    "option_b": "Acetylcholine",
    "option_c": "Norepinephrine",
    "option_d": "Glutamate",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine pathogenesis involves a complex interplay of neurotransmitters. Serotonin (5-hydroxytryptamine or 5-HT) is one of the key neurotransmitters implicated, both in the initiation of migraines and in the mechanism of action of several abortive treatments. A central theory in migraine is the dysregulation of serotonin levels in the brainstem, which can lead to the activation of the trigeminovascular system. This results in the release of vasoactive peptides, causing vasodilation and the neurogenic inflammation observed in migraine. The efficacy of triptans, which are 5-HT1 receptor agonists, supports the role of serotonin in migraine pathogenesis. Clinically, the pulsating headache, accompanied by nausea, photophobia, and sometimes aura, is linked to fluctuations in serotonin. The modulation of serotonin receptors by medications can abort or prevent these attacks, correlating well with migraine pathophysiology. Diagnosis of migraine is largely clinical, based on the International Classification of Headache Disorders (ICHD) criteria. Differentiation from other primary headache disorders, such as tension-type headache or cluster headache, is based on the presence of migrainous features (nausea, photophobia, phonophobia) and the pulsating quality of the pain. For acute migraine attacks, triptans (targeting 5-HT1 receptors) are the mainstay. Preventive therapies may include beta-blockers, antiepileptics, and CGRP antagonists. In pregnant or lactating women, the use of triptans is generally limited; acetaminophen is often preferred for acute treatment, and non-pharmacologic management strategies are emphasized. Preventive therapy in pregnancy may involve careful use of beta-blockers, weighing maternal benefits against fetal risks. Option A (Serotonin) is the correct answer because its modulation is central to migraine pathogenesis, and many effective migraine therapies specifically target serotonin receptors. Option B (Acetylcholine), Option C (Norepinephrine), and Option D (Glutamate) have roles in various central nervous system processes but are less directly implicated as the primary neurotransmitter in migraine pathogenesis when compared to serotonin. 1. Triptans work by agonizing 5-HT1 receptors, directly linking serotonin to migraine treatment. 2. A decrease in serotonin levels is a well-established component of migraine outbreaks, triggering the trigeminovascular cascade. Recent research continues to refine our understanding of migraine neurobiology, including the role of serotonin as well as newer targets like CGRP. The evolving guidelines endorse serotonin receptor targeting and advocate for personalized therapy based on patient profiles, especially when considering treatment in special populations such as pregnant or breastfeeding women.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with migraine did brain MRI as a routine work up of chronic headache which showed white matter lesions, what is the most appropriate action?",
    "option_a": "Aquaporin 4 abs.",
    "option_b": "Schirmer's test",
    "option_c": "Reassurance",
    "option_d": "High signals in the corpus callosum",
    "option_e": "Susac syndrome",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "In migraine patients, incidental white matter lesions on brain MRI are frequently encountered. These lesions, usually seen as T2/FLAIR hyperintensities, are common in patients with migraine and typically do not indicate an alternative neurological disease. The white matter lesions observed in migraine are thought to result from transient microvascular changes and possible small vessel ischemia related to repeated episodes of cortical spreading depression. Although the exact mechanism remains under study, the changes appear benign and are not associated with progressive demyelination like that in multiple sclerosis. Patients with migraine who present with these lesions rarely show additional neurological deficits attributable to the MRI findings. Their clinical course remains consistent with migraine rather than evolving into other demyelinating or inflammatory processes. Differential diagnoses include multiple sclerosis (often with lesions in the corpus callosum and periventricular regions), small vessel ischemic disease, and conditions such as Susac syndrome. However, in the appropriate clinical setting of migraine without atypical features, these lesions are interpreted as incidental. Detailed clinical history and correlation with physical exam findings help secure the diagnosis. The current guidelines recommend no further invasive workup or aggressive management for these lesions. The appropriate action is reassurance with continued migraine management. In pregnancy and lactation, unnecessary additional testing is avoided, and the focus remains on safe, symptomatic treatment of migraine. Option A (Aquaporin 4 abs) is used to evaluate neuromyelitis optica, not migraine. Option B (Schirmer's test) is used for evaluating Sj\u00f6gren\u2019s syndrome. Option D (High signals in the corpus callosum) would raise suspicion for multiple sclerosis, and Option E (Susac syndrome) involves a distinct triad affecting the brain, retina, and cochlea. Thus, reassurance (Option C) is the best management step. 1. White matter hyperintensities in migraine are a common, benign finding. 2. Always interpret MRI findings within the clinical context to avoid unnecessary testing. 3. There is no evidence that these lesions predict worse clinical outcomes in migraine. Recent studies have confirmed that these incidental lesions do not translate into higher morbidity. Current guidelines emphasize clinical correlation and reassurance rather than further examination if no other concerning features are present.",
    "exam_year": "2018",
    "exam_type": "Part I",
    "image_url": "page_4.png"
  },
  {
    "question": "A 40-year-old woman is seen in consultation for chronic daily headaches. She takes acetaminophen twice daily and oral sumatriptan 3 to 4 times per week. A medication-overuse headache (MOH) is suspected. Which of the following associated features would be most supportive of a diagnosis of MOH in this patient?",
    "option_a": "absence of neck pain",
    "option_b": "absence of rhinorrhea",
    "option_c": "constant frontal location",
    "option_d": "mild severity",
    "option_e": "worsened severity upon awakening",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Medication-overuse headache (MOH) is a secondary headache disorder that occurs in patients with a preexisting primary headache who frequently use acute headache medications. The repeated use of medications\u2014such as triptans and simple analgesics\u2014leads to neuroadaptive changes and central sensitization. This results in a headache pattern that is often daily and of altered character compared to the patient\u2019s primary headache type. Patients with MOH commonly present with chronic daily headaches that are typically less severe compared to classical migraine attacks. The overuse of medication can blunt the intensity of the headache, resulting in what is described as a mild or moderate, yet persistent, headache. The diagnostic approach includes a detailed history to document the frequency and dose of medication use, clinical features of the headache, and exclusion of other causes. Common differential diagnoses are chronic migraine, chronic tension-type headache, and new daily persistent headache. The ICHD-3 criteria require headaches on \u226515 days/month along with medication overuse for at least 3 months. First-line management involves withdrawing the overused medications (a process known as detoxification). Patient education and supportive care are crucial. Preventive therapies may be introduced cautiously once the overuse is addressed. In pregnancy and lactation, medication withdrawal should be done with careful monitoring and use of safe analgesics, considering non-pharmacological therapies as well. Option A (absence of neck pain) and Option B (absence of rhinorrhea) are not specific for MOH. Option C (constant frontal location) might describe a tension-type headache but is not a key supportive feature for MOH. Option E (worsened severity upon awakening) suggests other causes such as sleep-related headaches. Option D (mild severity) aligns with the clinical observation that the rebound headache in MOH is typically a persistent, less severe headache compared to the acute severe migraine attacks, making it the best supportive feature. 1. MOH is best suspected in patients with daily headache and a history of frequent, regular pain medication use. 2. The headache in MOH is often dull, constant, and of milder intensity than the patient\u2019s typical migraine attacks. 3. Successful management requires cessation of the overused medications. Recent guidelines underscore the importance of early recognition of MOH and emphasize medication withdrawal as the cornerstone of treatment. There is growing support for integrated behavioral and preventive strategies in managing MOH.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Visual aura for 10 seconds followed by headache, what is the most likely explanation?",
    "option_a": "Occipital seizures",
    "option_b": "Migraine aura",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Visual auras can be seen in both migraine and epileptic phenomena. The key differentiator between the two is the duration and progression of the visual symptom. Migraine aura is believed to result from cortical spreading depression\u2014a wave of neuronal and glial depolarization followed by inhibition\u2014leading to visual disturbances that typically build gradually and last several minutes. In contrast, occipital seizures are due to focal epileptiform discharges in the occipital cortex, producing brief, transient visual phenomena. Migraine auras usually last 5\u201360 minutes and follow a gradual onset with progression, whereas visual symptoms from occipital seizures are usually brief (lasting seconds) and stereotyped. The brief 10-second visual aura followed by headache in this case favors an epileptic origin (occipital seizure) over a typical migraine aura. When differentiating between migraine aura and occipital seizures, careful assessment of aura duration, progression, and associated symptoms is essential. An electroencephalogram (EEG) may assist in diagnosing occipital seizures. Differential diagnoses include transient ischemic attacks and other visual disturbances, but the brevity and stereotypy of the episode are more characteristic of a seizure. For occipital seizures, management typically involves antiepileptic medications; treatment choice in pregnancy or lactation must consider fetal safety (e.g., lamotrigine is generally considered safer). Migraine aura is managed with standard migraine treatments. Correct identification is crucial as management strategies differ significantly. Option A (Occipital seizures) correctly accounts for the brief (10-second) visual disturbance, which is much shorter than the typical migraine aura. Option B (Migraine aura) is incorrect because migraine auras generally last several minutes rather than seconds. The lack of additional options does not impact the determination that occipital seizures best explain the presentation. 1. Visual phenomena lasting only a few seconds point more toward an epileptic event than migraine. 2. Duration and evolution of the aura are key factors in differentiating between migraine aura and occipital seizures. 3. Occipital seizures may be accompanied by a headache in the postictal phase. Recent research highlights the importance of detailed history-taking in patients with transient visual symptoms. Guidelines stress the role of EEG in confirming epileptic events and differentiating them from migraine auras, especially when the duration is atypically short.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Prior to prescribing oral contraceptive pills, evaluating for potential hypercoagulable states is most necessary in which of the following populations?",
    "option_a": "women with basilar migraine",
    "option_b": "women with chronic daily headache",
    "option_c": "women with menstrual migraine",
    "option_d": "women with migraine with aura",
    "option_e": "women with ophthalmoplegic migraine",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Migraine with aura is recognized as an independent risk factor for ischemic stroke, and estrogen-containing oral contraceptive pills (OCPs) can further elevate this risk. Assessing for hypercoagulable states is particularly important in these patients prior to prescribing OCPs. Migraine with aura involves cortical spreading depression, which may predispose to transient cerebral vascular changes and a prothrombotic state. When combined with the estrogen in OCPs, which increases clotting factors, there is a heightened risk of thromboembolic events, particularly ischemic stroke. Women with migraine with aura have been shown in multiple studies to be at a higher risk of stroke, especially if other risk factors (e.g., smoking, age over 35) are present. This risk mandates careful evaluation of hypercoagulable factors before initiating estrogen-containing contraception. The evaluation involves a thorough personal and family history for thrombotic events and, when indicated, laboratory testing for hypercoagulable states. Differential considerations include other migraine subtypes (basilar, menstrual, ophthalmoplegic, chronic daily headaches) which do not have the same level of thrombotic risk as migraine with aura. Guidelines contraindicate the use of estrogen-containing OCPs in women with migraine with aura, particularly in those over 35 or with additional risk factors for thrombosis. Alternative contraceptive methods, such as progestin-only pills or intrauterine devices, are recommended. In pregnancy and lactation, non-estrogen methods are preferred to avoid thrombotic risk and hormonal exposure. Option A (women with basilar migraine) is concerning but does not carry as high a risk of thrombotic complications as migraine with aura. Option B (chronic daily headache) and Option C (menstrual migraine) are not specifically associated with hypercoagulability. Option E (ophthalmoplegic migraine) is rare and does not confer the same risk. Therefore, Option D (women with migraine with aura) is the most critical population for evaluation. 1. Always assess the thrombotic risk in women with migraine with aura before prescribing estrogen-containing contraceptives. 2. Alternative methods of contraception should be considered in high-risk patients. 3. The risk of ischemic stroke is markedly increased when migraine with aura is combined with estrogen use. The latest guidelines from both neurology and gynecology societies emphasize avoiding estrogen-containing OCPs in women with migraine with aura due to the increased risk of ischemic stroke, and they advocate for comprehensive risk factor assessment, including hypercoagulable states, before initiating such therapy.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Visual aura for 10-20 minutes followed by headache",
    "option_a": "Migraine",
    "option_b": "",
    "option_c": "",
    "option_d": "etails does not change the fact that the clinical scenario is pathognomonic for migraine.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine with aura is a primary headache disorder that typically presents with a fully reversible neurological disturbance (most commonly visual) preceding the headache phase. A visual aura lasting 10-20 minutes followed by headache is a classical presentation of migraine with aura. Aura is believed to result from cortical spreading depression\u2014a wave of neuronal and glial depolarization that spreads across the cerebral cortex, particularly starting in the occipital lobe. This phenomenon leads to transient changes in cerebral blood flow and subsequent trigeminovascular activation, which is thought to trigger the headache phase. Patients often describe visual phenomena such as scintillations, zigzag lines, or scotomas before the onset of a unilateral, pulsating headache accompanied by nausea, photophobia, and phonophobia. Recognizing this temporal pattern is critical for distinguishing migraine with aura from other neurological conditions like transient ischemic attacks (TIAs). Diagnosis is primarily clinical based on patient history using criteria from the International Classification of Headache Disorders (ICHD). Differential diagnoses include TIA, epilepsy-related visual disturbances, and other primary headache disorders. A careful history regarding the duration, character, and associated symptoms of the aura and headache is key. Acute migraine management includes NSAIDs and triptans, initiated once the headache is established. Prophylactic treatments (beta-blockers, antiepileptics, or calcium channel blockers) may be considered for frequent episodes. During pregnancy, medications must be chosen carefully: for instance, NSAIDs are avoided in the third trimester, while sumatriptan (a triptan) may be used if benefits outweigh potential risks. In lactation, agents with minimal transfer into breast milk are preferred. Option A, Migraine, is correct because a visual aura lasting 10-20 minutes followed by headache is the hallmark of migraine with aura. The absence of other option details does not change the fact that the clinical scenario is pathognomonic for migraine. 1) Migraine auras typically last 5-60 minutes, most often around 10-20 minutes. 2) A detailed history is crucial to differentiate migraine aura from other neurological events like TIA. 3) In patients with migraine with aura, additional cardiovascular risk factors (such as smoking or oral contraceptive use) require careful evaluation. Latest ICHD criteria and various clinical studies continue to support cortical spreading depression as the mechanism behind migraine aura. Novel neuromodulation techniques and tailored prophylactic regimens are being evaluated to improve patient outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Triptans may be used for migraine management in patients with which of the following comorbidities?",
    "option_a": "coronary artery disease",
    "option_b": "hemiplegic migraine",
    "option_c": "history of stroke",
    "option_d": "peptic ulcer disease",
    "option_e": "peripheral vascular disease",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Triptans are a class of serotonin receptor (5-HT1B/1D) agonists used in the acute treatment of migraine. Their vasoconstrictive properties specifically target cranial blood vessels and inhibit pro-inflammatory peptide release from trigeminal nerve endings. Triptans work by inducing vasoconstriction of dilated cranial blood vessels and by modulating neurotransmission in the trigeminovascular system. However, they also have a systemic vasoconstrictive effect, which makes them contraindicated in patients with conditions such as coronary artery disease, history of stroke, and peripheral vascular disease. Peptic ulcer disease is not related to vascular pathology, making it a safe comorbidity for triptan use. In clinical practice, triptans effectively relieve migraine symptoms in patients without significant cardiovascular comorbidities. When prescribing triptans, it is important to evaluate the patient's cardiovascular history to avoid complications. Patients with peptic ulcer disease do not have an increased risk of vascular side effects from triptans. Before initiating triptan therapy, clinicians should assess patients for contraindications by reviewing medical history for coronary artery disease, history of stroke, or peripheral vascular disease. Other acute migraine treatments may be considered for patients with these contraindications. First-line acute migraine treatment generally includes triptans in patients without contraindicating cardiovascular conditions. In pregnant patients, sumatriptan is considered if the therapeutic benefits outweigh the potential risks (recent studies suggest relative safety in pregnancy, though data are still emerging). In lactating women, sumatriptan is used cautiously due to low levels in breast milk. \u2022 Option A (Coronary artery disease): Contraindicated due to risk of coronary vasospasm. \u2022 Option B (Hemiplegic migraine): Typically avoided because of the risk of exacerbating stroke-like symptoms. \u2022 Option C (History of stroke): Contraindicated. \u2022 Option D (Peptic ulcer disease): Correct, since this comorbidity does not increase the risk of the vasoconstrictive effects of triptans. \u2022 Option E (Peripheral vascular disease): Contraindicated because of potential vasoconstrictive complications. 1) Always screen for cardiovascular disease before prescribing triptans. 2) Peptic ulcer disease does not pose a risk with triptan use, unlike coronary or cerebrovascular diseases. 3) Tailor acute migraine treatment based on individual patient comorbidities. Recent guidelines emphasize the importance of cardiovascular risk assessment prior to triptan prescription. Multiple studies support the safety of triptans in patients with non-vascular comorbidities such as peptic ulcer disease, while reaffirming contraindications in patients with known vascular disease.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of hemicrania continua, what is the first line treatment",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua is a primary headache disorder characterized by a continuous, strictly unilateral head pain with superimposed exacerbations, and it is uniquely responsive to indomethacin. While the precise mechanisms behind hemicrania continua remain not fully elucidated, hypotheses involve dysregulation of the trigeminal-autonomic reflex. The dramatic responsiveness to indomethacin suggests a distinct inflammatory or prostaglandin-mediated pathway in these patients. Patients typically present with continuous unilateral headache that may vary in intensity but always responds completely to indomethacin. This complete response is a diagnostic hallmark and helps differentiate hemicrania continua from other unilateral headache disorders like cluster headache or chronic migraine. The diagnosis is primarily clinical and confirmed by a therapeutic trial of indomethacin. Differential diagnoses include chronic migraine, cluster headache, and paroxysmal hemicrania. A positive indomethacin trial (complete resolution of pain) confirms hemicrania continua. Indomethacin is the first-line and diagnostic treatment for hemicrania continua. The dosing is typically initiated at 25-50 mg three times a day and may be titrated based on response. In pregnancy, indomethacin should be used with caution especially in the third trimester due to the risk of premature closure of the fetal ductus arteriosus. Alternative therapies in lactation are limited; management decisions should balance maternal benefit and potential neonatal risk. \u2022 Option A (Indomethacin) is the correct and only established treatment, given the complete therapeutic response seen in hemicrania continua. Other options were not provided, but no alternative medication has demonstrated comparable efficacy. 1) The dramatic response to indomethacin is considered pathognomonic for hemicrania continua. 2) Hemicrania continua is often misdiagnosed; an indomethacin trial is essential for accurate diagnosis. 3) Caution is required with indomethacin in pregnant patients due to potential fetal risks. Recent clinical reviews continue to endorse indomethacin as the gold standard treatment for hemicrania continua. Although research into the precise neuro-inflammatory pathways continues, there has been no successful alternative replacement therapy that matches the efficacy of indomethacin for this condition.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Triptan can be used with the following condition:",
    "option_a": "Peptic ulcer disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Triptans, such as sumatriptan, are serotonergic agents used for the acute management of migraine. They act as 5-HT1B/1D receptor agonists producing vasoconstriction and inhibition of pro-inflammatory neuropeptide release. The mechanism of action of triptans involves cranial vasoconstriction and modulation of trigeminal nerve activity, which helps alleviate migraine headaches. The vasoconstriction effect confines primarily to cranial vessels; therefore, in patients with peptic ulcer disease, which is not associated with vascular compromise, triptans do not pose the same risks as in patients with cardiovascular diseases. In clinical settings, triptans are used safely in patients who lack contraindicating cardiovascular or cerebrovascular conditions. Peptic ulcer disease does not affect the vasoconstrictive safety profile of triptans, making it an acceptable condition in which these agents can be used. Prior to prescribing triptans, a thorough evaluation of cardiovascular health is essential. Differential considerations include assessing the risk of coronary artery disease, cerebrovascular disease, and peripheral vascular disease, which are contraindications to triptan use. Peptic ulcer disease is not a risk factor for triptan-induced complications. Triptans remain first-line therapy for acute migraine attacks in appropriate patients. In patients with peptic ulcer disease, triptans are a favorable option because NSAIDs\u2014another common migraine treatment\u2014may exacerbate gastrointestinal conditions. In pregnancy, sumatriptan is often used when necessary, although it is categorized usually with cautionary advice (Category C) and only when benefits justify potential risks. In lactating women, triptans are considered relatively safe due to low levels of secretion in breast milk. \u2022 Option A (Peptic ulcer disease) is correct because peptic ulcer disease is not a contraindication for the use of triptans. The other conditions typically associated with triptan contraindications (coronary, cerebrovascular, or peripheral vascular disease) are not applicable here. 1) Triptans should be avoided in patients with significant cardiovascular disease but can be safely used in those with peptic ulcer disease. 2) NSAIDs may worsen peptic ulcer disease, so triptans can be a preferred option in such patients. 3) Always assess the full cardiovascular history before initiating triptan therapy. Recent research and updated guidelines continue to affirm that triptans are effective and safe for acute migraine management in patients without vascular comorbidities. Studies underscore the importance of a patient-tailored approach, particularly when considering alternative treatments for patients with concurrent peptic ulcer disease.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has irritable bowel syndrome, obese and has migraine what you will give as a prophylactic agent?",
    "option_a": "Topiramate",
    "option_b": "Valproate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Migraine prophylaxis aims to reduce the frequency, severity, and duration of migraine attacks. In this context, topiramate, an antiepileptic drug, is utilized not only for its migraine prophylactic effects but also for its beneficial impact on body weight, which is particularly relevant in obese patients. Topiramate works by blocking voltage-dependent sodium channels, enhancing the inhibitory neurotransmitter GABA, antagonizing glutamate receptors, and inhibiting carbonic anhydrase. These actions reduce neuronal hyperexcitability associated with migraine. Additionally, its appetite-suppressing effects contribute to weight loss, making it attractive in obese patients. Conversely, valproate, another antiepileptic used for migraine prophylaxis, tends to cause weight gain and holds a higher teratogenic risk. An obese patient with migraine and irritable bowel syndrome (IBS) benefits from topiramate due to its dual role in reducing migraine frequency and aiding weight management. The presence of IBS does not contraindicate topiramate, whereas the weight gain associated with valproate could worsen obesity-related issues. Migraine is primarily a clinical diagnosis based on characteristic headache features and associated symptoms. Differential diagnoses include tension-type headaches, cluster headaches, and secondary headache disorders. The patient\u2019s history and symptoms support a diagnosis of migraine. First-line prophylactic treatments for migraines include topiramate, propranolol, and amitriptyline. Topiramate is favored in obese individuals because of its weight loss properties. However, in pregnancy and lactation, its use is cautioned due to teratogenic risks (e.g., cleft lip/palate). Alternatives with a better safety profile during pregnancy should be considered in women of childbearing age. Option A (Topiramate) is appropriate because it provides effective migraine prophylaxis with the added benefit of weight loss, making it suitable for this patient. Option B (Valproate) is less ideal due to its propensity for weight gain and significant teratogenicity, particularly relevant for women of reproductive age. 1. Always tailor migraine prophylaxis to the patient\u2019s comorbidities; in obese patients, agents causing weight loss (like topiramate) are preferred. 2. Consider teratogenic risks when choosing prophylactic agents in women of childbearing potential. 3. Migraine remains a clinical diagnosis, but patient characteristics guide medication choice. Recent studies and clinical guidelines continue to endorse topiramate as an effective prophylactic agent for migraine, especially in patients where weight loss is a desired benefit. Ongoing research stresses the importance of individualized treatment plans taking comorbid conditions into account.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Male with occipital headache radiating to the frontal area, on exam he has tenderness over the occipital protuberance and headache worse with head movement What\u2019s the Rx:",
    "option_a": "Nerve block",
    "option_b": "Carbamazepine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Occipital neuralgia is a headache disorder marked by paroxysmal pain in the distribution of the occipital nerves. Diagnosis and treatment focus on alleviating nerve irritation. The condition is usually due to irritation or entrapment of the greater or lesser occipital nerves. This irritation can be secondary to muscle tightness, cervical spine pathology, or trauma, leading to sharp, shooting pain that is often reproducible on palpation over the occipital protuberance. The patient\u2019s presentation\u2014with occipital headache radiating to the frontal area, localized tenderness over the occipital protuberance, and exacerbation of pain with head movements\u2014is highly suggestive of occipital neuralgia. Differential diagnoses include tension-type headache, cervicogenic headache, and migraine. Diagnostic occipital nerve blocks are both a diagnostic tool and a therapeutic intervention, providing relief if the occipital nerves are the source of pain. The first-line management often involves occipital nerve blocks using local anesthetics, sometimes combined with corticosteroids to reduce inflammation. Adjunct therapies include physical therapy and neuropathic pain medications. For patients who are pregnant or lactating, nerve blocks are generally safe when performed using appropriate doses and agents with minimal systemic absorption. Option A (Nerve block) is correct because it serves as both a diagnostic and therapeutic measure in occipital neuralgia. Option B (Carbamazepine) is not indicated as it is primarily used for trigeminal neuralgia and does not address the pathology of occipital nerve irritation. 1. Occipital nerve blocks can confirm the diagnosis and provide temporary pain relief in occipital neuralgia. 2. Tenderness over the occipital protuberance is a hallmark sign. 3. Differentiate occipital neuralgia from tension-type and cervicogenic headaches based on physical findings and response to nerve blocks. Recent studies reinforce the use of occipital nerve blocks in treating occipital neuralgia, with many patients experiencing significant short-term relief. Updated clinical guidelines recommend a multimodal approach that may include nerve blocks, physical therapy, and consideration of neuropathic pain medications.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Young with trigeminal. Neuralgia what to do next?",
    "option_a": "(CT) is inadequate due to poor soft tissue resolution. Option B (Reassurance) is inappropriate as it delays the necessary diagnostic workup required in a younger patient where serious underlying conditions might be present. Option C (MRI) is correct, as it is the most sensitive imaging modality to evaluate the trigeminal nerve and exclude secondary causes. Option D (LP) is not indicated in the first",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is characterized by episodes of intense, lancinating facial pain. In young patients, it is critical to exclude secondary causes (e.g., multiple sclerosis or tumors) rather than attributing the pain solely to primary idiopathic trigeminal neuralgia. In classical trigeminal neuralgia, neurovascular compression leads to demyelination of the trigeminal nerve fibers. However, in younger patients, secondary causes such as demyelinating plaques from multiple sclerosis or compressive masses are more common, necessitating detailed imaging evaluation. Young patients with facial neuralgic pain require careful assessment because the likelihood of underlying pathology is higher compared to an older population where idiopathic causes are more prevalent. The differential diagnosis includes classic trigeminal neuralgia, multiple sclerosis-associated neuralgia, and neoplastic lesions. Magnetic resonance imaging (MRI) is the gold standard for visualizing the trigeminal nerve, surrounding vascular structures, and potential demyelinating or compressive pathologies. For young patients with suspected trigeminal neuralgia, the first step is an MRI to exclude secondary causes before initiating pharmacotherapy (such as carbamazepine). In pregnant or lactating patients, MRI is considered safe when specific protocols are followed, ensuring that no ionizing radiation is used. Option A (CT) is inadequate due to poor soft tissue resolution. Option B (Reassurance) is inappropriate as it delays the necessary diagnostic workup required in a younger patient where serious underlying conditions might be present. Option C (MRI) is correct, as it is the most sensitive imaging modality to evaluate the trigeminal nerve and exclude secondary causes. Option D (LP) is not indicated in the first-line evaluation unless there is a specific suspicion of CNS infection or inflammation. 1. Always perform an MRI in young patients with trigeminal neuralgia to rule out secondary causes such as multiple sclerosis. 2. Do not rely solely on clinical diagnosis in younger patients due to the higher risk of underlying pathology. 3. Early identification of a secondary cause can significantly alter management and prognosis. Latest clinical guidelines and studies emphasize the use of high-resolution MRI in young patients with trigeminal neuralgia. Recent research has validated MRI's superior sensitivity in detecting neurovascular contacts and demyelinating lesions, thereby guiding appropriate management.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Trigeminal neuralgia in young age, Dx",
    "option_a": "(MRI) is correct because it is the most sensitive method to identify neurovascular compressions, demyelinating plaques, or tumors. Option B (CT) is not appropriate due to its limited resolution for soft tissue detail. Option C (Clinical Dx) is insufficient on its own in young patients because it may miss secondary pathologies. Option D (LP) is not indicated unless there is suspicion of infection or inflammatory conditions, which is not the typical presentation.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is a debilitating facial pain syndrome. In young patients, the presentation demands thorough evaluation because of the increased likelihood of secondary causes which may require different management strategies. Typically, trigeminal neuralgia results from demyelination due to vascular compression of the trigeminal nerve. In younger individuals, similar demyelination might occur secondary to conditions like multiple sclerosis or compressive tumors, making detailed imaging critical. When younger patients present with trigeminal neuralgia, it is essential to confirm the diagnosis and rule out any secondary etiologies that may be responsible for the neuralgic pain. MRI provides a detailed evaluation of nerve integrity, demyelinating lesions, and vascular relationships. The diagnosis should involve a high-resolution MRI to differentiate between classical trigeminal neuralgia (due to vascular compression) and secondary trigeminal neuralgia (related to other pathologies like MS). The differential diagnosis also includes conditions such as atypical facial pain and cluster headache, although the clinical characteristics are distinct. After diagnosis, initial management typically includes pharmacological treatment (e.g., carbamazepine). However, the critical first step in young patients is to perform an MRI. MRI is safe during pregnancy and lactation when used without contrast or with appropriate safety measures, ensuring the exclusion of secondary causes before treatment. Option A (MRI) is correct because it is the most sensitive method to identify neurovascular compressions, demyelinating plaques, or tumors. Option B (CT) is not appropriate due to its limited resolution for soft tissue detail. Option C (Clinical Dx) is insufficient on its own in young patients because it may miss secondary pathologies. Option D (LP) is not indicated unless there is suspicion of infection or inflammatory conditions, which is not the typical presentation. 1. In young patients with trigeminal neuralgia, always obtain an MRI to exclude secondary causes. 2. MRI\u2019s superior soft tissue resolution makes it the imaging modality of choice in delineating neurovascular anatomy and identifying demyelinating lesions. 3. Early diagnosis can significantly impact treatment decisions and long-term outcomes. Recent guidelines and research advocate for MRI as the primary imaging modality in young patients presenting with trigeminal neuralgia. High-resolution MRI protocols have increased the detection rate of subtle pathological changes, optimizing patient management.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Male with very severe headache after Orgasm Then improved What would u do?",
    "option_a": "Indomethacin",
    "option_b": "Brain CT",
    "option_c": "Lumbar puncture",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "In any patient presenting with a sudden, very severe (thunderclap) headache \u2013 even if it occurs in a specific setting such as after orgasm \u2013 it is critical to rule out life\u2010threatening secondary causes. Brain imaging is the initial step in the evaluation of such headaches. Orgasm-induced headaches can be primary (benign) but may also herald secondary issues like subarachnoid hemorrhage, arterial dissection, or reversible cerebral vasoconstriction syndrome. The sudden spike in blood pressure and sympathetic stimulation during orgasm can, in susceptible individuals, trigger a vascular event. Current evidence stresses that even transient improvement does not exclude a serious vascular pathology. A male who develops a very severe headache immediately after orgasm, even if it improves, fits the profile of a thunderclap headache which requires urgent evaluation as the headache could be a sentinel event for an aneurysmal bleed or other vascular abnormality. The standard approach is to obtain an immediate non-contrast CT scan of the brain to assess for hemorrhage. If the CT scan is negative and clinical suspicion remains high, a lumbar puncture may be indicated to rule out a subarachnoid hemorrhage. Differential diagnoses include primary headache associated with sexual activity and secondary vascular events. First, urgent neuroimaging (non-contrast CT) is indicated. If imaging is unremarkable but suspicion persists, a lumbar puncture should be done. Further management depends on the underlying diagnosis. In cases confirmed as primary sexual headache, treatment options like pre-emptive indomethacin may be considered. There are no specific pregnancy or lactation issues in this instance, as the patient is male. Option A (Indomethacin) is used as prophylaxis in primary sexual headache but only after excluding serious conditions. Option B (Brain CT) is the correct initial step to rule out hemorrhage. Option C (Lumbar puncture) is appropriate only if CT imaging is negative while still maintaining a high suspicion for subarachnoid hemorrhage. Option D is not provided. 1. Thunderclap headache after exertion or sexual activity must first be evaluated for secondary causes. 2. A normal initial headache does not rule out a vascular event; always confirm with neuroimaging. 3. If CT is negative and clinical suspicion persists, follow-up with a lumbar puncture is warranted. Recent guidelines emphasize the need for urgent neuroimaging in cases of unusual, sudden-onset headaches for early detection of life-threatening conditions. Studies confirm that even transient improvement does not preclude serious vascular events, reinforcing CT as the first-line investigation.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant in her 8th month came with acute migraine what is the treatment",
    "option_a": "Ibuprofen",
    "option_b": "Sumatriptans",
    "option_c": "Hydrocodone",
    "option_d": "Dihydroergotamine",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Migraine management during pregnancy requires careful selection of medications to balance maternal relief with fetal safety. In the third trimester, certain analgesics and migraine-specific treatments are contraindicated due to their effects on the fetus. Migraine attacks are thought to involve neurovascular dysregulation and neurogenic inflammation. In pregnancy, hormonal fluctuations can modify migraine patterns. However, treatment choices must account for potential teratogenicity or adverse effects on uteroplacental circulation. An 8-month pregnant woman (third trimester) with an acute migraine attack needs effective pain relief, but options such as NSAIDs (e.g., ibuprofen) carry risks like premature closure of the ductus arteriosus. Dihydroergotamine and opioids like hydrocodone may also impose risks, making safety paramount. This is a clinical diagnosis of migraine, often made on the basis of patient history and headache characteristics. Differential diagnoses include tension-type headache and secondary headaches; however, the history typically confirms a migraine pattern. First-line treatment for migraine in pregnancy typically involves non-pharmacologic measures and acetaminophen; however, in moderate to severe cases where these are ineffective and considering the contraindications of NSAIDs in the third trimester, sumatriptan is considered a reasonable option. According to recent guidance, if after initial measures (hydration, rest, and antiemetics like metoclopramide) the attack persists, sumatriptan may be used cautiously. It has the most evidence among triptans for use in pregnancy, with no substantial increase in congenital malformations. Always weigh risks and benefits in both pregnancy and lactation contexts. Option A (Ibuprofen) is contraindicated in the third trimester due to risk of premature ductus arteriosus closure. Option B (Sumatriptans) is the best option among those listed, as data support its relatively safe profile in pregnancy when necessary. Option C (Hydrocodone) carries risks of neonatal respiratory depression and dependency. Option D (Dihydroergotamine) is contraindicated due to its potent vasoconstrictive properties, which can adversely affect uterine blood flow. 1. Always avoid NSAIDs in the third trimester of pregnancy to prevent fetal complications. 2. Sumatriptan, though not first-line in the general population, is acceptable in pregnancy when other safer options are not effective. 3. Non-pharmacologic measures and supportive care should be optimized before utilizing migraine-specific medications in pregnancy. Recent observational studies and guideline updates from headache societies suggest that sumatriptan does not significantly increase fetal risks when used appropriately. Current consensus advises that, after careful assessment, sumatriptan offers a balance between efficacy and safety in the management of acute migraines in pregnant patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with migraine came with new onset of headache unlike previous migraine headache, not improving despite increase analgesic dose and frequency. what is the diagnosis?",
    "option_a": "chronic daily headache",
    "option_b": "Medication overuse headache",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Medication Overuse Headache (MOH) is a secondary headache disorder where regular overuse of symptomatic headache medications transforms episodic migraine into a chronic daily headache. Recognizing a change in headache pattern in a known migraine patient is vital. MOH is believed to result from neuroadaptive changes in central pain processing pathways due to sustained exposure to analgesics. Overuse leads to increased headache frequency and a reduction in headache threshold, ultimately inducing a rebound phenomenon characterized by a new pattern of headache. A migraine patient who presents with a new type of headache that is different from their typical migraine, and who reports worsening headache despite increasing doses of analgesics, is highly suggestive of MOH. This is often seen when patients inadvertently worsen their headache burden by overusing pain medications. Diagnosis of MOH is clinical and based on a detailed medication history. Differential diagnoses include transformation to chronic migraine or new secondary headaches. Key features include headache occurring on 15 or more days per month in a patient with a pre-existing headache disorder and regular overuse of acute medications. The first-line management of MOH is withdrawal of the offending medication, combined with education and supportive therapy. Adjunctive therapies include the use of preventive headache medications after a period free of overuse, and patient monitoring is essential. In pregnancy, management is supportive; abrupt withdrawal should be undertaken cautiously and with close follow-up to avoid withdrawal symptoms, while considering safe alternatives. Option A (Chronic Daily Headache) is a descriptive term for headache frequency and may be a consequence of MOH, but it does not explain the mechanism behind the worsening headache pattern. Option B (Medication Overuse Headache) precisely explains the scenario where frequent use of analgesics paradoxically worsens headache frequency and intensity. Options C and D are not provided. 1. Always inquire about medication frequency in patients with worsening headache patterns. 2. MOH is a preventable cause of chronic headache if patients are educated on proper medication use. 3. Tapering off overused medications is the cornerstone of treatment. Recent guidelines emphasize the importance of early recognition and management of MOH. Studies highlight that withdrawal therapy, combined with patient education, leads to significant improvement in headache frequency. Updated ICHD-3 criteria provide structured diagnostic guidelines for MOH.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "How to differentiate between TACs:",
    "option_a": "Duration",
    "option_b": "Response to Rx",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral headache pain with prominent cranial autonomic features. Differentiating among TACs relies on detailed clinical history including attack duration, frequency, and response to specific treatments. TACs are thought to involve hypothalamic activation, which results in trigeminal-autonomic reflex activation. Variations in the duration, frequency, and intensity of autonomic symptoms are closely linked to the underlying neural mechanisms differentiating cluster headache, paroxysmal hemicrania, and SUNCT. For instance, cluster headaches typically last 15-180 minutes, paroxysmal hemicrania lasts 2-30 minutes, and SUNCT attacks last seconds to minutes. The differentiation by duration is crucial as it helps direct the clinician toward the correct diagnosis and management plan. Diagnosis of TACs is primarily clinical. A careful history that documents the exact duration of headache episodes, as well as their frequency and associated autonomic features (tearing, rhinorrhea, eyelid edema), is essential. Other differentials include migraine with autonomic symptoms, which is differentiated by its longer duration and different pattern of symptoms. Management of TACs varies by subtype. For example, cluster headache is treated with high-flow oxygen and triptans as first line, paroxysmal hemicrania responds dramatically to indomethacin, and SUNCT management can be challenging often involving antiepileptics. These treatment decisions are based on accurately differentiating the TAC subtype, for which attack duration is a key diagnostic criterion. There are no pregnancy or lactation specific issues mentioned in this question. Option A (Duration) is correct because the length of each headache attack is one of the most reliable distinguishing factors among TACs. Option B (Response to Rx) is also used in certain cases (for instance, the dramatic response of paroxysmal hemicrania to indomethacin) but is less universally applicable than duration when distinguishing all TACs. Options C and D are not provided. 1. Duration of headache attacks is one of the most critical factors in differentiating between various TACs. 2. A marked response to indomethacin is pathognomonic for paroxysmal hemicrania. 3. Thorough patient history remains invaluable in diagnosing TAC subtypes. Current guidelines and research from headache societies reiterate that duration, along with attack frequency and autonomic features, should be the cornerstone in differentiating TACs. While treatment response (especially in paroxysmal hemicrania) is important, duration remains the primary criterion in the clinical setting.",
    "exam_year": "2019",
    "exam_type": "Part I"
  }
]